Latest RMD news and sentiment

ResMed Inc. $RMD Stock Position Raised by Railway Pension Investments Ltd

Railway Pension Investments Ltd significantly increased its stake in ResMed Inc. (NYSE:RMD) by 406% in Q2, bringing its total holdings to $9.5 million. ResMed reported strong financial results, beating earnings expectations with $2.95 EPS and $1.46 billion in revenue, and increased its quarterly dividend. Despite these positive financial indicators, analysts hold a cautious "Hold" rating on the stock with an average price target of $240.31.

Quantitative Investment Management LLC Invests $2.21 Million in ResMed Inc. $RMD

Quantitative Investment Management LLC recently acquired 11,360 shares of ResMed Inc. (NYSE:RMD) valued at approximately $2.21 million during the second quarter. ResMed reported strong quarterly earnings, exceeding estimates with $2.95 EPS and an 8.6% increase in revenue year-over-year. The company also raised its quarterly dividend to $0.66 per share, resulting in an annualized yield of 1.1%, while analysts maintain a consensus "Hold" rating with a target price of $240.31.

ResMed Inc. (NYSE:RMD) Given Average Rating of "Hold" by Brokerages

ResMed Inc. (NYSE:RMD) has received an average "Hold" rating from brokerages, with ten out of seventeen analysts recommending a neutral stance and seven advising a buy. The average 12-month price target is set at approximately $240.31. The company recently reported strong quarterly adjusted earnings of $2.95 per share, surpassing estimates, and increased its quarterly dividend from $0.60 to $0.66 per share.

KeyBanc Adjusts Price Target on ResMed to $267 From $255, Keeps Overweight Rating

Manulife buys $14.4M ResMed stake as revenue climbs 8.6%

The Manufacturers Life Insurance Company has acquired 73,774 shares of ResMed Inc., valued at approximately $14.38 million. This investment comes as ResMed reported an 8.6% increase in quarterly revenue to $1.46 billion, meeting Wall Street expectations. The purchase highlights continued institutional interest in healthcare and medical-technology sectors, despite some insider share sales and a "Hold" consensus rating from analysts.

GTS Securities LLC Has $2.05 Million Holdings in ResMed Inc. $RMD

GTS Securities LLC significantly increased its stake in ResMed Inc. ($RMD) by 659.1% in the second quarter, bringing its holdings to 10,514 shares valued at approximately $2.05 million. ResMed exceeded quarterly earnings expectations with $2.95 EPS and reported an 8.6% increase in revenue year-over-year. Analysts currently maintain a "Hold" rating with a consensus target price of $239.38, and the company recently raised its quarterly dividend to $0.66 per share.

Freestone Grove Partners LP Invests $1.52 Million in ResMed Inc. $RMD

Freestone Grove Partners LP has acquired a new position in ResMed Inc. (NYSE:RMD) during the second quarter, purchasing 7,826 shares valued at approximately $1.52 million. This comes as other institutional investors have also adjusted their holdings in ResMed, while company insiders have sold shares totaling over $2.8 million. ResMed recently announced an increase in its quarterly dividend and reported earnings that beat analyst estimates.

ResMed stock holds above $240 as latest earnings beat expectations

Ieq Capital LLC Acquires New Position in ResMed Inc. $RMD

Ieq Capital LLC has acquired a new stake in ResMed Inc. (NYSE:RMD), purchasing 9,387 shares valued at approximately $1.83 million during the second quarter. Other institutional investors also adjusted their positions in RMD. The article also details recent insider stock sales, analyst rating changes, and ResMed's financial performance, including a recent dividend increase.

Cibc World Market Inc. Acquires New Holdings in ResMed Inc. $RMD

Cibc World Market Inc. has acquired a new position in ResMed Inc., purchasing 30,963 shares valued at approximately $6 million during the second quarter. ResMed recently reported strong quarterly earnings, beating analyst expectations with $2.95 per share and an 8.6% increase in revenue, and also raised its quarterly dividend from $0.60 to $0.66 per share. Despite some insider selling, institutional investors own 54.98% of the stock, and analysts maintain a consensus "Hold" rating with an average price target of $239.38.

Parkman Healthcare Partners LLC Makes New Investment in ResMed Inc. $RMD

Parkman Healthcare Partners LLC has made a new investment in ResMed Inc. (NYSE:RMD), acquiring 32,983 shares valued at approximately $6.4 million in the second quarter, increasing institutional ownership to 54.98%. The medical equipment provider recently reported strong quarterly earnings, beating estimates with $2.95 EPS and an 8.6% revenue increase, and also raised its quarterly dividend from $0.60 to $0.66 per share. Despite some insider selling, analysts maintain a consensus "Hold" rating for the stock with a target price of $239.38.

Osmosis Investment Management UK Ltd Makes New $2.16 Million Investment in ResMed Inc. $RMD

Osmosis Investment Management UK Ltd has made a new investment of $2.16 million in ResMed Inc., acquiring 11,081 shares. This comes amidst other institutional investors also adjusting their positions in ResMed, while analysts have issued various ratings and price targets for the stock. ResMed recently reported strong quarterly earnings, beating consensus estimates, and announced an increase in its quarterly dividend.

Korea Investment CORP Invests $9.85 Million in ResMed Inc. $RMD

Korea Investment CORP has acquired a new position in ResMed Inc. (NYSE:RMD), purchasing 50,523 shares valued at approximately $9.85 million during the second quarter. This investment is part of broader institutional interest, with hedge funds and institutions owning 54.98% of ResMed. The medical equipment provider recently reported strong quarterly earnings, beating analyst estimates, and increased its quarterly dividend.

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in ResMed Inc. $RMD

Connor Clark & Lunn Investment Management Ltd. has acquired a new stake in ResMed Inc. (NYSE:RMD), purchasing 142,297 shares valued at approximately $27.73 million, representing about 0.10% of the company. Other hedge funds also adjusted their positions in RMD, while ResMed recently reported strong quarterly earnings, increased its dividend, and saw some insider selling. Analysts have issued varied ratings on the stock, with a consensus "Hold" rating and an average target price of $239.38.

Polymer Capital Management HK LTD Makes New $972,000 Investment in ResMed Inc. $RMD

Polymer Capital Management HK LTD has made a new investment of $972,000 in ResMed Inc. (NYSE:RMD), purchasing 4,990 shares. Other institutional investors like Hsbc Holdings PLC, Goldman Sachs Group Inc., BlackRock Inc., Fideuram Asset Management Ireland dac, and Legal & General Plc have also adjusted their holdings in ResMed. The company recently increased its quarterly dividend and reported strong quarterly earnings that beat analyst estimates.

9,773 Shares in ResMed Inc. $RMD Bought by Callan Family Office LLC

Callan Family Office LLC has acquired a new position in ResMed Inc. (NYSE:RMD), purchasing 9,773 shares valued at approximately $1.905 million. Other institutional investors have also recently bought and sold shares of ResMed, with institutional ownership standing at 54.98%. ResMed has reported strong financial performance, including beating analysts' earnings estimates, increasing its quarterly dividend, and experiencing insider selling activity by its CEO and a director.

Vista Investment Management Invests $920,000 in ResMed Inc. $RMD

Vista Investment Management has acquired 4,722 shares of ResMed Inc. (NYSE:RMD) totaling approximately $920,000, increasing institutional ownership to 54.98%. Despite significant insider selling and mixed analyst ratings, ResMed exceeded earnings expectations with an EPS of $2.95 and revenue of $1.46 billion, also increasing its quarterly dividend to $0.66 per share. The company maintains a consensus "Hold" rating from analysts with an average price target of $239.38.

78,381 Shares in ResMed Inc. $RMD Purchased by Quantbot Technologies LP

Quantbot Technologies LP recently acquired 78,381 shares of ResMed Inc. (NYSE:RMD) during the second quarter, valued at approximately $15.28 million, making it their 7th largest holding. Other institutional investors have also adjusted their stakes in ResMed, while analysts have issued various price targets and ratings, resulting in a consensus "Hold" rating with an average target price of $239.38. ResMed also announced an increase in its quarterly dividend to $0.66 per share and reported insider stock sales by its director and CEO.